Free Trial

Genmab A/S (GMAB) Competitors

Genmab A/S logo
$29.89 +0.02 (+0.07%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$29.88 0.00 (-0.02%)
As of 10/24/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GMAB vs. ARGX, TAK, ONC, INSM, BNTX, TEVA, SMMT, ASND, RDY, and VTRS

Should you be buying Genmab A/S stock or one of its competitors? The main competitors of Genmab A/S include argenex (ARGX), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

Genmab A/S vs. Its Competitors

argenex (NASDAQ:ARGX) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

argenex has a net margin of 40.98% compared to Genmab A/S's net margin of 37.53%. argenex's return on equity of 21.06% beat Genmab A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
argenex40.98% 21.06% 18.25%
Genmab A/S 37.53%21.03%16.98%

argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

60.3% of argenex shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genmab A/S has higher revenue and earnings than argenex. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenex$2.25B22.35$833.04M$19.5041.91
Genmab A/S$3.12B6.15$1.14B$1.9915.02

In the previous week, argenex had 2 more articles in the media than Genmab A/S. MarketBeat recorded 15 mentions for argenex and 13 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.80 beat argenex's score of 0.44 indicating that Genmab A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
argenex
4 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Genmab A/S
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

argenex presently has a consensus target price of $817.53, indicating a potential upside of 0.03%. Genmab A/S has a consensus target price of $40.80, indicating a potential upside of 36.50%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than argenex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
argenex
0 Sell rating(s)
3 Hold rating(s)
20 Buy rating(s)
1 Strong Buy rating(s)
2.92
Genmab A/S
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.82

Summary

argenex beats Genmab A/S on 11 of the 17 factors compared between the two stocks.

Get Genmab A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GMAB vs. The Competition

MetricGenmab A/SMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.19B$3.46B$6.21B$10.81B
Dividend YieldN/A2.28%5.72%4.80%
P/E Ratio15.0228.5131.6030.98
Price / Sales6.15497.40595.06133.64
Price / Cash19.7146.9537.2561.86
Price / Book3.7210.4012.056.61
Net Income$1.14B-$52.83M$3.34B$277.10M
7 Day Performance-9.89%2.10%1.94%2.57%
1 Month Performance2.82%10.17%6.88%3.20%
1 Year Performance29.28%16.57%56.06%33.22%

Genmab A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GMAB
Genmab A/S
3.8371 of 5 stars
$29.89
+0.1%
$40.80
+36.5%
+29.3%$19.19B$3.12B15.022,682Analyst Forecast
Short Interest ↑
Analyst Revision
ARGX
argenex
2.6927 of 5 stars
$799.56
+0.3%
$817.53
+2.2%
+46.8%$48.77B$2.25B41.001,599News Coverage
Upcoming Earnings
Analyst Downgrade
TAK
Takeda Pharmaceutical
2.2461 of 5 stars
$13.72
+0.0%
N/A+3.4%$43.62B$30.09B8.9047,455News Coverage
Upcoming Earnings
ONC
BeOne Medicines
3.0111 of 5 stars
$327.03
+2.2%
$340.30
+4.1%
N/A$35.08B$3.81B0.0011,000Positive News
Analyst Forecast
INSM
Insmed
3.066 of 5 stars
$163.94
+1.0%
$149.06
-9.1%
+125.0%$34.31B$363.71M0.001,271News Coverage
Upcoming Earnings
Analyst Forecast
BNTX
BioNTech
2.5768 of 5 stars
$102.30
+0.2%
$134.32
+31.3%
-4.4%$24.54B$2.98B0.006,772News Coverage
Analyst Forecast
TEVA
Teva Pharmaceutical Industries
3.7093 of 5 stars
$20.02
-0.1%
$25.57
+27.8%
+5.8%$22.97B$16.54B8.0136,830Positive News
Analyst Forecast
SMMT
Summit Therapeutics
2.7968 of 5 stars
$22.93
+7.4%
$31.29
+36.4%
-9.3%$15.86B$700K0.00110Trending News
Earnings Report
Analyst Forecast
Insider Trade
Analyst Revision
Gap Up
ASND
Ascendis Pharma A/S
2.7197 of 5 stars
$208.43
-0.5%
$248.29
+19.1%
+55.0%$12.93B$393.54M0.001,017Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7407 of 5 stars
$14.36
+0.1%
$16.95
+18.1%
-4.4%$11.97B$3.81B21.7327,811News Coverage
Earnings Report
Analyst Forecast
Gap Up
VTRS
Viatris
2.9844 of 5 stars
$9.86
+1.2%
$10.40
+5.5%
-9.5%$11.36B$14.74B4.0432,000Analyst Forecast

Related Companies and Tools


This page (NASDAQ:GMAB) was last updated on 10/26/2025 by MarketBeat.com Staff
From Our Partners